First U.S. Food and Drug Administration (FDA) release for electroCore, a neuroscience and technology company - Hand-held, non-invasive, easy-to-use device provides new option for the approximately 400,000 Americans living with this rare but extremely debilitating headache disorder Basking Ridge,
Data from ACT2 Clinical Trial of gammaCore ® in Cluster Headache Presented for First Time Yesterday During Emerging Science Session Basking Ridge, NJ, April 26, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement,
Data from Pooled Analysis of ACT1 and ACT2 To Be Presented in Late-Breaking Oral Session at Annual Scientific Meeting of the American Headache Society Basking Ridge, NJ, June 8, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
Regulatory clearance marks most recent achievement in new device being available to the approximately 400,000 Americans living with episodic cluster headaches Basking Ridge, NJ, June 15, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through
Francis R. Amato to Take on Additional Role to Help Further Position the Company for Growth Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that Chief Executive
Peter Staats MD, MBA, ABIPP, FIPP Joins electroCore to Lead Global Development of Company’s Non-invasive Vagus Nerve Stimulation (nVNS) Therapy Basking Ridge, NJ, June 21, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological
electroCore launches gammaCore Patient Registry (GPR) to provide access to hand-held, easy-to-use device for the acute treatment of pain associated with episodic cluster headache in adults Basking Ridge, NJ, July 18, 2017 – electroCore, a neuroscience and technology company dedicated to
Nick Colucci Brings Invaluable Healthcare Communications Expertise to Enhance electroCore’s Continued Growth Basking Ridge, NJ, August 29, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, today announced that
PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham Basking Ridge, NJ, September 11, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced the first results
Investment to fund commercialization of gammaCore ® and further clinical development of nVNS Basking Ridge, NJ, November 29, 2017 – electroCore, a U.S.-based bioelectronic medicine healthcare company advancing better patient therapies through superior approaches to neuromodulation, announced